Image Place holder

Javier Pinilla-Ibarz, MD, PhD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

My clinical interest is in the area of chronic leukemias with special interest in chronic myeloid leukemia and chronic lymphoid leukemias.

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • La Paz University Hospital, Madrid, Spain - Hematology and Hematotherapy
  • Memorial Sloan-Kettering Cancer Center - Medical Oncology & Hematology
  • Memorial Sloan-Kettering Cancer Center, Dept of Leukemia - Immunology

Residency:

  • La Paz University Hospital, Madrid, Spain - Internal Medicine
  • New York Presbyterian/Cornell Medical Center - Internal Medicine

Medical School:

  • University of Zaragoza Medical School - MD
Participating Trials

CLINICAL TRIAL 18539
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); ACP-196 (Acalabrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

CLINICAL TRIAL 19151
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Condition: Malignant Hematology
Intervention: Chlorambucil; Obinutuzumab; TGR-1202; Ublituximab
Open

CLINICAL TRIAL 17967
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: KTE-C19; Levetiracetam; Tocilizumab; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition: Malignant Hematology
Intervention: KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition: Malignant Hematology
Intervention: SL-401
Open

CLINICAL TRIAL 18365
Preliminary Evaluation of an Internet-Assisted Cognitive Behavioral Intervention for Targeted Therapy Fatigue
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 19080
A Phase II Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Condition: Malignant Hematology
Intervention: MLN0128; TAK-228 (MLN0128)
Open

CLINICAL TRIAL 19070
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 Mar;102(3):519-528. Pubmedid: 27927766. Pmcid: PMC5394958.
  • Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Jun;1-10. Pubmedid: 28641468.
  • Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, Hancock W, Seto E, Villagra A, Yu XZ, Sotomayor EM. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. 2017 Jul;130(2):146-155. Pubmedid: 28550044. Pmcid: PMC5510785.
  • Hussaini MO, Rehman A, Chavez JC, Pinilla-Ibarz J, Horna P. EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Jul;58(7):1753-1756. Pubmedid: 27852142.
  • Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):78-82. Pubmedid: 28082112.
  • Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug;123(15):2875-2880. Pubmedid: 28387926. Pmcid: PMC5573914.
  • Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, Seto E, Sotomayor EM, Horna P, Pinilla-Ibarz J. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. J Leukoc Biol. 2017 Aug;102(2):475-486. Pubmedid: 28550123.
  • Sweet K, Pinilla-Ibarz J. NCCN and ELN: What do the guidelines tell us?. Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. Pubmedid: 27839567.
  • Poort H, Meade CD, Knoop H, Gielissen MF, Pinilla-Ibarz J, Jacobsen PB. Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs. 2016 Nov. Pubmedid: 27832018. Pmcid: PMC5422141.
  • Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-296. Pubmedid: 26993758. Pmcid: PMC4965237.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May;91(5):E280-E283. Pubmedid: 26875020.
  • Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KS, Montecino M, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Seto E, Weber J, Sotomayor EM, Villagra A. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016 May;10(5):735-750. Pubmedid: 26775640. Pmcid: PMC4870131.
  • Sweet K, Pinilla-Ibarz J. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Crit Rev Oncol Hematol. 2016 Jul;103:99-108. Pubmedid: 27262540.
  • Emole J, Talabi T, Pinilla-Ibarz J. Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics. 2016 Feb;10:23-31. Pubmedid: 27013862. Pmcid: PMC4777272.
  • Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2117-2125. Pubmedid: 27660167. Pmcid: PMC5116249.
  • Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016 Aug;9:4937-4957. Pubmedid: 27570458. Pmcid: PMC4986686.
  • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug;47:78-83. Pubmedid: 27285853.
  • Pinilla-Ibarz J, Emole J. Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. Cancer Control. 2015 Oct;22(4 Suppl):7-16. Pubmedid: 26618341.
  • Pinilla-Ibarz J, Chavez JC. Life after ibrutinib? A new unmet need in CLL. Blood. 2015 Mar;125(13):2013-2014. Pubmedid: 25814485.
  • Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S14-S18. Pubmedid: 26297266.
  • Fradley MG, Pinilla-Ibarz J. Arrhythmic complications of tyrosine kinase inhibitors. Future Cardiol. 2015 Jul;11(4):395-399. Pubmedid: 26238220.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul;90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, A L AS, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015 Feb;63(2):579-585. Pubmedid: 25155994. Pmcid: PMC4252813.
  • Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Anticancer Res. 2015 Dec;35(12):6355-6364. Pubmedid: 26637844.
  • Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KS, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015 Aug;9(7):1447-1457. Pubmedid: 25957812. Pmcid: PMC4523430.
  • Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy. 2015 Apr;7(4):455-466. Pubmedid: 25917633.
  • Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, Villagra A, Sotomayor EM. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol. 2014 Sep;193(6):2850-2862. Pubmedid: 25108026. Pmcid: PMC4157123.
  • Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct;38(10):1165-1172. Pubmedid: 24889511. Pmcid: PMC4625795.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov;55(11):2660-2662. Pubmedid: 24528217.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.
  • Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014 Jun;124(6):2585-2598. Pubmedid: 24812669. Pmcid: PMC4038575.
  • Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014 Jul;39(7):483-519. Pubmedid: 25083126. Pmcid: PMC4103574.
  • Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol. 2014 Jul;60(1):44-53. Pubmedid: 24747960. Pmcid: PMC4020151.
  • Sweet K, Pinilla-Ibarz J, Zhang L. Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Prefer Adherence. 2014 Jul;8:981-986. Pubmedid: 25045255. Pmcid: PMC4099191.
  • Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec;100(6):567-574. Pubmedid: 25281405.
  • O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Deangelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Ne. 2013 Nov;11(11):1327-1340. Pubmedid: 24225967. Pmcid: PMC4234105.
  • Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013 May;8:37-45. Pubmedid: 23717217. Pmcid: PMC3662532.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul;88(7):566-570. Pubmedid: 23605934. Pmcid: PMC4685468.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul;19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
  • Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013 Jul;6:54. Pubmedid: 23870290. Pmcid: PMC3737033.
  • Brayer JB, Pinilla-Ibarz J. Developing strategies in the immunotherapy of leukemias. Cancer Control. 2013 Jan;20(1):49-59. Pubmedid: 23302907. Pmcid: PMC4689299.
  • Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: Combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. 2013 Dec;88(3):667-679. Pubmedid: 23969231.
  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.
  • Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res. 2012 Sep;72(17):4440-4448. Pubmedid: 22728650. Pmcid: PMC3990429.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Pinilla-Ibarz J, Flinn I. The expanding options for front-line treatment in patients with newly diagnosed CML. Crit Rev Oncol Hematol. 2012 Nov;84(2):287-299. Pubmedid: 22487423.
  • Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res. 2012 Jun;36(6):756-763. Pubmedid: 22209738. Pmcid: PMC3331955.
  • Tombleson RL, Ho V, Sokol L, Pinilla J, Wetzstein GA. Optimizing premedications in the prevention of bendamustine infusion-related reactions. Cancer Control. 2012 Jul;19(3):245-247. Pubmedid: 22710900.
  • Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control. 2012 Jan;19(1):37-53. Pubmedid: 22143061.
  • Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control. 2012 Jan;19(1):54-67. Pubmedid: 22143062.
  • Desai S, Pinilla-Ibarz J. Front-line therapy for chronic lymphocytic leukemia. Cancer Control. 2012 Jan;19(1):26-36. Pubmedid: 22143060.
  • Pinilla-Ibarz J. Chronic lymphocytic leukemia: new choices for an old condition. Cancer Control. 2012 Jan;19(1):4-5. Pubmedid: 22143057.
  • O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F. Chronic myelogenous leukemia. J Natl Compr Canc Ne. 2012 Jan;10(1):64-110. Pubmedid: 22223870.
  • Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012 Aug;120(5):1027-1038. Pubmedid: 22692508. Pmcid: PMC3680046.
  • Veliz M, Pinilla-Ibarz J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med. 2012 Aug;2:71-77. Pubmedid: 22287865. Pmcid: PMC3262343.
  • McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol. 2012 Aug;2012:513702. Pubmedid: 22888354. Pmcid: PMC3409527.
  • Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leuk Res. 2011 Sep;35(9):1193-1199. Pubmedid: 21377729. Pmcid: PMC4607255.
  • Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May;117(21):5600-5606. Pubmedid: 21467546. Pmcid: PMC4186645.
  • Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May;29(15):e434-e436. Pubmedid: 21149648.
  • Bello C, Veliz M, Pinilla-Ibarz J. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Expert Rev Clin Immunol. 2011 May;7(3):295-300. Pubmedid: 21595596.
  • Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res. 2011 Mar;35(3):394-404. Pubmedid: 20863567. Pmcid: PMC4458853.
  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.
  • Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011 Mar;(62):71.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan;117(4):1141-1145. Pubmedid: 21098399. Pmcid: PMC4916554.
  • Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2011 Feb;117(4):688-697. Pubmedid: 20922786.
  • O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Ne. 2011 Feb;9 Suppl 2:S1-25. Pubmedid: 21335443. Pmcid: PMC4234100.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteom Clin Appl. 2011 Aug;5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.
  • Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr;52(4):668-679. Pubmedid: 21271862. Pmcid: PMC4487410.
  • Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr;186(7):3986-3996. Pubmedid: 21368229. Pmcid: PMC3998678.
  • Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 2010 Jun;116(11):2665-2672. Pubmedid: 20310049. Pmcid: PMC2876208.
  • Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul;131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.
  • Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010 Jul;116(2):171-179. Pubmedid: 20400682. Pmcid: PMC2910606.
  • Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des. 2010 Jan;16(3):268-276. Pubmedid: 20109136.
  • Pinilla-Ibarz J, McQuary A. Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control. 2010 Apr;17(2 Suppl):4-15. Pubmedid: 20404796.
  • Pinilla-Ibarz J, Quintas-Cardama A. New agents in the treatment of chronic myelogenous leukemia. J Natl Compr Canc Ne. 2009 Oct;7(9):1028-1037. Pubmedid: 19878642.
  • O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Ne. 2009 Oct;7(9):984-1023. Pubmedid: 19878641.
  • Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 May;15(10):3406-3415. Pubmedid: 19401350.
  • Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan;10(1):92-100. Pubmedid: 19011628. Pmcid: PMC3925685.
  • Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 2009 Apr;16(2):100-107. Pubmedid: 19337196.
  • Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control. 2009 Apr;16(2):141-152. Pubmedid: 19337200.
  • Kharfan-Dabaja M, Chavez J, Khorfan K, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer. 2008 Sep;113(5):897-906. Pubmedid: 18618518.
  • Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep. 2008 Sep;10(5):365-371. Pubmedid: 18706263.
  • Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther. 2008 Oct;7(10):3169-3175. Pubmedid: 18852120. Pmcid: PMC2676735.
  • Pidala J, Pinilla-Ibarz J, Cualing HD. A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). Cancer Genet Cytogenet. 2008 Apr;182(1):46-49. Pubmedid: 18328951.
  • May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007 Aug;13(15 Pt 1):4547-4555. Pubmedid: 17671141.
  • Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS, Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res. 2006 Oct;30(10):1293-1298. Pubmedid: 16533527.
  • Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 2006 Mar;107(5):2045-2051. Pubmedid: 16269613. Pmcid: PMC1895712.
  • Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005 Oct;90(10):1324-1332. Pubmedid: 16219568.
  • Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol. 2004 Sep;76(3):623-633. Pubmedid: 15197237.
  • Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004 Feb;103(3):1037-1042. Pubmedid: 14504104.
  • Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May;99(10):3748-3755. Pubmedid: 11986232.